Cision PR Newswire

Curis to review results during conference call, featuring commentary by Dr. Eric Winer, M.D., Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m. ET LEXINGTON, Mass., Dec. 5, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it will host a webcast on Monday, December 12, 2022, at 10:00 a.m. ET to discuss new data from the TakeAim Leukemia trial of …

(PRNewsfoto/Curis, Inc.)

PALM SPRINGS, Calif., Dec. 5, 2022 /PRNewswire/ -- On Walt Disney's birthday, Monday, December 5, 2022, at 5:30 PM there will be a VIP Birthday Party in honor of Walt Disney in celebration of the opening of a new exhibit to accompany Walt Disney's Grumman Gulfstream 1 Airplane. Rarely exhibited items from the aircraft's interior will be on display to visitors at the Palm Springs Air Museum. Items include a customized instrument panel originally located near Walt's favorite onboard seat that allowed …

(PRNewsfoto/Palm Springs Air Museum)

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Schmitt To Contact Him Directly To Discuss Their Options NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Schmitt Industries, Inc. ("Schmitt" or the "Company") (NASDAQ: SMIT) and reminds investors of the December 12, 2022 deadline to seek the role of lead plaintiff in a federal …

Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP)

Collaboration between Korea's top-notch tech companies expected to bolster Korea's edge in AI competitivenessNAVER to provide its expertise in software, including hyperscale AI and compression algorithms, for developing a semiconductor solution for AIHyperCLOVA to be used from the initial stages of development to develop and verify solutions that address the actual needs that arise from using hyperscale AISamsung Electronics to develop semiconductor solutions that can solve bottlenecks in large-scale …

NAVER Corporation Logo

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. ("Veru" or the "Company") (NASDAQ: VERU). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Veru and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inspirato Incorporated ("Inspirato" or the "Company") (NASDAQ: ISPO). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Inspirato and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK , Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iris Energy Limited ("Iris" or the "Company") (NASDAQ: IREN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Iris and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Provident Bancorp, Inc. ("Provident or the "Company") (NASDAQ: PVBC). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Provident and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK , Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TuSimple Holding Inc. ("TuSimple" or the "Company") (NASDAQ: TSP). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether TuSimple and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Leidos Holdings Inc. ("Leidos" or the "Company") (NYSE: LDOS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Leidos and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Spectrum and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Bioventus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inotiv, Inc. ("Inotiv" or the "Company") (NASDAQ: NOTV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Inotiv and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK , Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Silvergate Capital Corporation ("Silvergate" or the "Company") (NYSE: SI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Silvergate and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or the "Company") (NASDAQ: VERV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Verve and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ: TMCI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Treace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK , Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SQZ Biotechnologies Company ("SQZ" or the "Company") (NYSE: SQZ). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether SQZ and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Wallbox N.V. ("Wallbox" or the "Company") (NYSE: WBX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Wallbox and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Twist and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

NEW YORK , Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lincoln National Corporation ("Lincoln" or the "Company") (NYSE: LNC). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Lincoln and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)